Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

The promises of PCSK9 inhibition.

Petrides F, Shearston K, Chatelais M, Guilbaud F, Meilhac O, Lambert G.

Curr Opin Lipidol. 2013 Aug;24(4):307-12. doi: 10.1097/MOL.0b013e328361f62d. Review.

PMID:
23817198
[PubMed - indexed for MEDLINE]
2.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
[PubMed - indexed for MEDLINE]
Free Article
3.

Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.

Kohli P, Desai NR, Giugliano RP, Kim JB, Somaratne R, Huang F, Knusel B, McDonald S, Abrahamsen T, Wasserman SM, Scott R, Sabatine MS.

Clin Cardiol. 2012;35(7):385-91. doi: 10.1002/clc.22014. Epub 2012 Jun 19.

PMID:
22714699
[PubMed - indexed for MEDLINE]
4.

Proprotein convertase subtilisin/kexin type 9: a new target molecule for gene therapy.

Banaszewska A, Piechota M, Plewa R.

Cell Mol Biol Lett. 2012 Jun;17(2):228-39. doi: 10.2478/s11658-012-0006-7. Epub 2012 Feb 7. Review.

PMID:
22311433
[PubMed - indexed for MEDLINE]
5.

Proprotein convertase subtilisin kexin9 (PCSK9): a novel target for cholesterol regulation.

Basak A, Palmer-Smith H, Mishra P.

Protein Pept Lett. 2012 Jun 1;19(6):575-85. Review.

PMID:
22519528
[PubMed - indexed for MEDLINE]
6.

The PCSK9 decade.

Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK.

J Lipid Res. 2012 Dec;53(12):2515-24. doi: 10.1194/jlr.R026658. Epub 2012 Jul 17. Review.

PMID:
22811413
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Anti-PCSK9 therapies for the treatment of hypercholesterolemia.

Hooper AJ, Burnett JR.

Expert Opin Biol Ther. 2013 Mar;13(3):429-35. doi: 10.1517/14712598.2012.748743. Epub 2012 Dec 17. Review.

PMID:
23240807
[PubMed - indexed for MEDLINE]
8.

Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.

Stein EA, Swergold GD.

Curr Atheroscler Rep. 2013 Mar;15(3):310. doi: 10.1007/s11883-013-0310-3. Review.

PMID:
23371064
[PubMed - indexed for MEDLINE]
9.

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.

Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, Strack AM, Wang F, Pandit S, Hammond H, Wood D, Lewis D, Rosa R, Mendoza V, Cumiskey AM, Johns DG, Hansen BC, Shen X, Geoghagen N, Jensen K, Zhu L, Wietecha K, Wisniewski D, Huang L, Zhao JZ, Ernst R, Hampton R, Haytko P, Ansbro F, Chilewski S, Chin J, Mitnaul LJ, Pellacani A, Sparrow CP, An Z, Strohl W, Hubbard B, Plump AS, Blom D, Sitlani A.

Int J Biol Sci. 2012;8(3):310-27. doi: 10.7150/ijbs.3524. Epub 2012 Feb 9.

PMID:
22355267
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

PCSK9 inhibitors.

Farnier M.

Curr Opin Lipidol. 2013 Jun;24(3):251-8. doi: 10.1097/MOL.0b013e3283613a3d. Review.

PMID:
23652470
[PubMed - indexed for MEDLINE]
11.

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

Urban D, Pöss J, Böhm M, Laufs U.

J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. Review.

PMID:
23973703
[PubMed - indexed for MEDLINE]
12.

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.

Poirier S, Mayer G.

Drug Des Devel Ther. 2013 Oct 4;7:1135-48. doi: 10.2147/DDDT.S36984. eCollection 2013. Review.

PMID:
24115837
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA.

J Am Coll Cardiol. 2012 Jun 19;59(25):2344-53. doi: 10.1016/j.jacc.2012.03.007. Epub 2012 Mar 28.

PMID:
22463922
[PubMed - indexed for MEDLINE]
Free Article
14.

PCSK9: a key modulator of cardiovascular health.

Seidah NG, Awan Z, Chrétien M, Mbikay M.

Circ Res. 2014 Mar 14;114(6):1022-36. doi: 10.1161/CIRCRESAHA.114.301621. Review.

PMID:
24625727
[PubMed - indexed for MEDLINE]
15.

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.

Shen L, Peng H, Xu D, Zhao S.

Pharmacol Res. 2013 Jul;73:27-34. doi: 10.1016/j.phrs.2013.04.001. Epub 2013 Apr 8. Review.

PMID:
23578522
[PubMed - indexed for MEDLINE]
16.

Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.

Lopez D.

Drug News Perspect. 2008 Jul-Aug;21(6):323-30. doi: 10.1358/dnp.2008.21.6.1246795. Review.

PMID:
18836590
[PubMed - indexed for MEDLINE]
17.

Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.

Betteridge DJ.

Nat Rev Endocrinol. 2013 Feb;9(2):76-8. doi: 10.1038/nrendo.2012.254. Epub 2013 Jan 8. Review.

PMID:
23296165
[PubMed - indexed for MEDLINE]
19.

Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.

Seidah NG.

Curr Pharm Des. 2013;19(17):3161-72. Review.

PMID:
23317404
[PubMed - indexed for MEDLINE]
20.

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

Giugliano RP, Desai NR, Kohli P, Rogers WJ, Somaratne R, Huang F, Liu T, Mohanavelu S, Hoffman EB, McDonald ST, Abrahamsen TE, Wasserman SM, Scott R, Sabatine MS; LAPLACE-TIMI 57 Investigators.

Lancet. 2012 Dec 8;380(9858):2007-17. doi: 10.1016/S0140-6736(12)61770-X. Epub 2012 Nov 6.

PMID:
23141813
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk